Clinical Research Directory
Browse clinical research sites, groups, and studies.
Remimazolam in High Risk ERCP Patients
Sponsor: National Taiwan University Hospital
Summary
We conducted a randomized trial to investigate whether the administration of Remimazolam in patients undergoing high-risk endoscopic retrograde cholangiopancreatography (ERCP) could significantly reduce the occurrence of intraoperative hypotension, facilitate rapid induction, and result in fewer associated complications.
Official title: Exploring the Use of Remimazolam (BYFAVO®) in Patients at High Risk for ERCP to Reduce Intraoperative Hypotension and Assess Safety and Efficacy: A Randomized Controlled Trial
Key Details
Gender
All
Age Range
20 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-02-15
Completion Date
2030-12-31
Last Updated
2024-02-16
Healthy Volunteers
No
Interventions
Remimazolam
novel ultra-short-acting benzodiazepine-like anesthetic.
placebo
normal saline (compared to Remimazolam)